Paroxetine Controlled Release for Premenstrual Dysphoric Disorder: Remission Analysis Following a Randomized, Double-Blind, Placebo-Controlled Trial
- PMID: 15841196
- PMCID: PMC1079696
- DOI: 10.4088/pcc.v07n0203
Paroxetine Controlled Release for Premenstrual Dysphoric Disorder: Remission Analysis Following a Randomized, Double-Blind, Placebo-Controlled Trial
Abstract
Objective: To compare the efficacy and safety of paroxetine controlled release (CR) (12.5 mg/day or 25 mg/day) versus placebo in premenstrual dysphoric disorder (PMDD).Method: A double-blind, randomized, placebo-controlled trial was conducted over 3 menstrual cycles in women aged 18-45 years with confirmed DSM-IV PMDD in 47 outpatient centers across the United States and Canada from November 1999 to January 2002. The primary efficacy measure was the visual analog scale (VAS)-Mood, which is the mean of 4 core symptoms: irritability, tension, depressed mood, and affective lability.Results: A statistically significant difference was observed in favor of paroxetine CR 25 mg versus placebo on the VAS-Mood (adjusted mean difference = -12.58 mm, 95% CI = -18.40 to -6.76; p < .001) and for paroxetine CR 12.5 mg versus placebo (adjusted mean difference = -7.51 mm, 95% CI = -13.40 to -1.62; p = .013). Paroxetine CR was generally well tolerated.Conclusion: Paroxetine CR doses of 12.5 mg/day and 25 mg/day are effective in treating PMDD and are well tolerated.
Figures
Similar articles
-
Paroxetine controlled release for premenstrual dysphoric disorder: a double-blind, placebo-controlled trial.Psychosom Med. 2004 Sep-Oct;66(5):707-13. doi: 10.1097/01.psy.0000140005.94790.9c. Psychosom Med. 2004. PMID: 15385695 Clinical Trial.
-
Luteal phase administration of paroxetine for the treatment of premenstrual dysphoric disorder: a randomized, double-blind, placebo-controlled trial in Canadian women.J Clin Psychiatry. 2008 Jun;69(6):991-8. doi: 10.4088/jcp.v69n0616. J Clin Psychiatry. 2008. PMID: 18517289 Clinical Trial.
-
Luteal phase dosing with paroxetine controlled release (CR) in the treatment of premenstrual dysphoric disorder.Am J Obstet Gynecol. 2005 Aug;193(2):352-60. doi: 10.1016/j.ajog.2005.01.021. Am J Obstet Gynecol. 2005. PMID: 16098854 Clinical Trial.
-
Paroxetine controlled release.CNS Drugs. 2004;18(6):355-64; discussion 365-6. doi: 10.2165/00023210-200418060-00003. CNS Drugs. 2004. PMID: 15089103 Review.
-
Effects of GABA active steroids in the female brain with a focus on the premenstrual dysphoric disorder.J Neuroendocrinol. 2018 Feb;30(2). doi: 10.1111/jne.12553. J Neuroendocrinol. 2018. PMID: 29072794 Review.
Cited by
-
Premenstrual dysphoric disorder: burden of illness and treatment update.J Psychiatry Neurosci. 2008 Jul;33(4):291-301. J Psychiatry Neurosci. 2008. PMID: 18592027 Free PMC article.
-
The effect of a social network-based cognitive behavioral therapy intervention on the severity of premenstrual syndrome symptoms: a protocol of a randomized clinical trial study.Trials. 2022 Apr 23;23(1):346. doi: 10.1186/s13063-022-06290-0. Trials. 2022. PMID: 35461297 Free PMC article.
-
Cognitive-behavioral and pharmacological interventions for premenstrual syndrome or premenstrual dysphoric disorder: a meta-analysis.J Clin Psychol Med Settings. 2012 Sep;19(3):308-19. doi: 10.1007/s10880-012-9299-y. J Clin Psychol Med Settings. 2012. PMID: 22426857 Review.
-
Selective serotonin reuptake inhibitors for premenstrual syndrome and premenstrual dysphoric disorder.Cochrane Database Syst Rev. 2024 Aug 14;8(8):CD001396. doi: 10.1002/14651858.CD001396.pub4. Cochrane Database Syst Rev. 2024. PMID: 39140320 Free PMC article.
-
Criteria for premenstrual dysphoric disorder: secondary analyses of relevant data sets.Arch Gen Psychiatry. 2012 Mar;69(3):300-5. doi: 10.1001/archgenpsychiatry.2011.1368. Arch Gen Psychiatry. 2012. PMID: 22393222 Free PMC article.
References
-
- American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington, DC: American Psychiatric Association. 1994
-
- Johnson SR, McChesney C, Bean JA.. Epidemiology of premenstrual symptoms in a non-clinical sample, 1: prevalence, natural history and help-seeking behavior. J Reprod Med. 1988;33:340–346. - PubMed
-
- Rivera-Tovar AD, Frank E.. Late luteal phase dysphoric disorder in young women. Am J Psychiatry. 1990;147:1634–1636. - PubMed
-
- Wittchen HU, Becker E, and Lieb R. et al. Prevalence, incidence and stability of premenstrual dysphoric disorder in the community. Psychol Med. 2002 32:119–132. - PubMed
-
- Sternfeld B, Swindle R, and Chawla A. et al. Severity of premenstrual symptoms in a health maintenance organization population. Obstet Gynecol. 2002 99:1014–1024. - PubMed
LinkOut - more resources
Full Text Sources